LuxturnaTM is an AAV designed to be administered to the sub-retinal space through the pars-plana approach, which carries the RPE65 gene to restore the deficiency in the RPE65 protein in patients with LCA with a biallelic RPE65 mutation. Here, RPE65 is linked to Leber congenital amaurosis.